5:28 PM
 | 
Sep 09, 2013
 |  BC Extra  |  Clinical News

Neurocrine's NBI-98854 misses in tardive dyskinesia trial

Neurocrine Biosciences Inc. (NASDAQ:NBIX) said once-daily 50 mg oral NBI-98854 missed the primary endpoint in 99 patients in the intent-to-treat (ITT) population of the Phase IIb Kinect Study to treat tardive dyskinesia. NBI-98854 did not reduce mean Abnormal Involuntary Movements Scale (AIMS) score from baseline to week six vs. placebo...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >